William Blair Restarts uniQure Coverage at $73, Sees Path for Huntington’s Gene Therapy
William Blair restarts QURE coverage with a $73 estimate, citing a clearer FDA path for AMT-130 in Huntington’s and cash funding into 2030.
William Blair restarts QURE coverage with a $73 estimate, citing a clearer FDA path for AMT-130 in Huntington’s and cash funding into 2030.
Four banks initiate coverage of Latigo after its IPO, citing LTG-001, 2027 data, and cash runway into 2028 for non-opioid pain drugs.
Capricor stock jumped after Piper Sandler turned bullish, citing a better risk-reward into the Nov. 22 FDA ruling on its DMD therapy.
Piper Sandler double-downgraded MYGN, saying the current model cannot grow or cut its way to profit.
Tenax’s TNX-103 missed the LEVEL primary endpoint. Guggenheim cites encouraging subgroup data in sicker patients but says more work and longer studies may be needed.
Analysts cite ziltivekimab’s trial miss, modest Medicare upside and patent risks.